Cargando…
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
BACKGROUND: Many treatments are being assessed for repurposing to treat coronavirus disease 2019 (COVID-19). One drug that has shown promising results in vitro is nitazoxanide. Unlike other postulated drugs, nitazoxanide shows a high ratio of maximum plasma concentration (C(max)), after 1 day of 500...
Autores principales: | Pepperrell, Toby, Pilkington, Victoria, Owen, Andrew, Wang, Junzheng, Hill, Andrew M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mediscript Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332204/ https://www.ncbi.nlm.nih.gov/pubmed/32405422 |
Ejemplares similares
-
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020) -
Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022) -
407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19
por: Wang, Junzheng, et al.
Publicado: (2021) -
891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV
por: Levi, Jacob, et al.
Publicado: (2021) -
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
por: Rodgers, Florence, et al.
Publicado: (2021)